Addition of pamidronate to chemotherapy for the treatment of osteosarcoma

Paul A. Meyers, John H. Healey, Alexander Ja-Ho Chou, Leonard H. Wexler, Pamela R. Merola, Carol D. Morris, Michael P. Laquaglia, Michael G. Kellick, Sara J. Abramson, Richard Gorlick

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background: This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma. Methods: The authors treated 40 patients with osteosarcoma with cisplatin, doxorubicin, and methotrexate with the addition of pamidronate 2 mg/kg/dose (max dose 90 mg) monthly for 12 doses. Survival, event-free survival (EFS), and durability of orthopedic reconstruction were evaluated. Results: For patients with localized disease, event-free survival (EFS) at 5 years was 72% and overall survival 93%. For patients with metastatic disease, EFS at 5 years was 45% and overall survival 64%. Toxicity was similar to patients treated with chemotherapy alone. Thirteen of 14 uncemented implants demonstrated successful osteointegration. Among allograft reconstructions, there were 2 graft failures, 4 delayed unions, and 6 successful grafts. Overall, 5 of 33 reconstructions failed. There were no stress fractures or growth disturbances. Conclusions: Pamidronate can be safely incorporated with chemotherapy for the treatment of osteosarcoma. It does not impair the efficacy of chemotherapy. Pamidronate may improve the durability of limb reconstruction.

Original languageEnglish (US)
Pages (from-to)1736-1744
Number of pages9
JournalCancer
Volume117
Issue number8
DOIs
StatePublished - Apr 15 2011

Fingerprint

pamidronate
Osteosarcoma
Disease-Free Survival
Drug Therapy
Survival
Transplants
Therapeutics
Stress Fractures
Methotrexate
Doxorubicin
Cisplatin
Orthopedics
Allografts
Extremities
Safety

Keywords

  • bisphosphonates
  • chemotherapy
  • endoprosthetic reconstruction
  • limb-sparing surgery
  • osteosarcoma
  • pamidronate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Meyers, P. A., Healey, J. H., Chou, A. J-H., Wexler, L. H., Merola, P. R., Morris, C. D., ... Gorlick, R. (2011). Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer, 117(8), 1736-1744. https://doi.org/10.1002/cncr.25744

Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. / Meyers, Paul A.; Healey, John H.; Chou, Alexander Ja-Ho; Wexler, Leonard H.; Merola, Pamela R.; Morris, Carol D.; Laquaglia, Michael P.; Kellick, Michael G.; Abramson, Sara J.; Gorlick, Richard.

In: Cancer, Vol. 117, No. 8, 15.04.2011, p. 1736-1744.

Research output: Contribution to journalArticle

Meyers, PA, Healey, JH, Chou, AJ-H, Wexler, LH, Merola, PR, Morris, CD, Laquaglia, MP, Kellick, MG, Abramson, SJ & Gorlick, R 2011, 'Addition of pamidronate to chemotherapy for the treatment of osteosarcoma', Cancer, vol. 117, no. 8, pp. 1736-1744. https://doi.org/10.1002/cncr.25744
Meyers PA, Healey JH, Chou AJ-H, Wexler LH, Merola PR, Morris CD et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer. 2011 Apr 15;117(8):1736-1744. https://doi.org/10.1002/cncr.25744
Meyers, Paul A. ; Healey, John H. ; Chou, Alexander Ja-Ho ; Wexler, Leonard H. ; Merola, Pamela R. ; Morris, Carol D. ; Laquaglia, Michael P. ; Kellick, Michael G. ; Abramson, Sara J. ; Gorlick, Richard. / Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. In: Cancer. 2011 ; Vol. 117, No. 8. pp. 1736-1744.
@article{a3a4ba5f4dd34112bf7d404b80cfbfff,
title = "Addition of pamidronate to chemotherapy for the treatment of osteosarcoma",
abstract = "Background: This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma. Methods: The authors treated 40 patients with osteosarcoma with cisplatin, doxorubicin, and methotrexate with the addition of pamidronate 2 mg/kg/dose (max dose 90 mg) monthly for 12 doses. Survival, event-free survival (EFS), and durability of orthopedic reconstruction were evaluated. Results: For patients with localized disease, event-free survival (EFS) at 5 years was 72{\%} and overall survival 93{\%}. For patients with metastatic disease, EFS at 5 years was 45{\%} and overall survival 64{\%}. Toxicity was similar to patients treated with chemotherapy alone. Thirteen of 14 uncemented implants demonstrated successful osteointegration. Among allograft reconstructions, there were 2 graft failures, 4 delayed unions, and 6 successful grafts. Overall, 5 of 33 reconstructions failed. There were no stress fractures or growth disturbances. Conclusions: Pamidronate can be safely incorporated with chemotherapy for the treatment of osteosarcoma. It does not impair the efficacy of chemotherapy. Pamidronate may improve the durability of limb reconstruction.",
keywords = "bisphosphonates, chemotherapy, endoprosthetic reconstruction, limb-sparing surgery, osteosarcoma, pamidronate",
author = "Meyers, {Paul A.} and Healey, {John H.} and Chou, {Alexander Ja-Ho} and Wexler, {Leonard H.} and Merola, {Pamela R.} and Morris, {Carol D.} and Laquaglia, {Michael P.} and Kellick, {Michael G.} and Abramson, {Sara J.} and Richard Gorlick",
year = "2011",
month = "4",
day = "15",
doi = "10.1002/cncr.25744",
language = "English (US)",
volume = "117",
pages = "1736--1744",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Addition of pamidronate to chemotherapy for the treatment of osteosarcoma

AU - Meyers, Paul A.

AU - Healey, John H.

AU - Chou, Alexander Ja-Ho

AU - Wexler, Leonard H.

AU - Merola, Pamela R.

AU - Morris, Carol D.

AU - Laquaglia, Michael P.

AU - Kellick, Michael G.

AU - Abramson, Sara J.

AU - Gorlick, Richard

PY - 2011/4/15

Y1 - 2011/4/15

N2 - Background: This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma. Methods: The authors treated 40 patients with osteosarcoma with cisplatin, doxorubicin, and methotrexate with the addition of pamidronate 2 mg/kg/dose (max dose 90 mg) monthly for 12 doses. Survival, event-free survival (EFS), and durability of orthopedic reconstruction were evaluated. Results: For patients with localized disease, event-free survival (EFS) at 5 years was 72% and overall survival 93%. For patients with metastatic disease, EFS at 5 years was 45% and overall survival 64%. Toxicity was similar to patients treated with chemotherapy alone. Thirteen of 14 uncemented implants demonstrated successful osteointegration. Among allograft reconstructions, there were 2 graft failures, 4 delayed unions, and 6 successful grafts. Overall, 5 of 33 reconstructions failed. There were no stress fractures or growth disturbances. Conclusions: Pamidronate can be safely incorporated with chemotherapy for the treatment of osteosarcoma. It does not impair the efficacy of chemotherapy. Pamidronate may improve the durability of limb reconstruction.

AB - Background: This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma. Methods: The authors treated 40 patients with osteosarcoma with cisplatin, doxorubicin, and methotrexate with the addition of pamidronate 2 mg/kg/dose (max dose 90 mg) monthly for 12 doses. Survival, event-free survival (EFS), and durability of orthopedic reconstruction were evaluated. Results: For patients with localized disease, event-free survival (EFS) at 5 years was 72% and overall survival 93%. For patients with metastatic disease, EFS at 5 years was 45% and overall survival 64%. Toxicity was similar to patients treated with chemotherapy alone. Thirteen of 14 uncemented implants demonstrated successful osteointegration. Among allograft reconstructions, there were 2 graft failures, 4 delayed unions, and 6 successful grafts. Overall, 5 of 33 reconstructions failed. There were no stress fractures or growth disturbances. Conclusions: Pamidronate can be safely incorporated with chemotherapy for the treatment of osteosarcoma. It does not impair the efficacy of chemotherapy. Pamidronate may improve the durability of limb reconstruction.

KW - bisphosphonates

KW - chemotherapy

KW - endoprosthetic reconstruction

KW - limb-sparing surgery

KW - osteosarcoma

KW - pamidronate

UR - http://www.scopus.com/inward/record.url?scp=79953783840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953783840&partnerID=8YFLogxK

U2 - 10.1002/cncr.25744

DO - 10.1002/cncr.25744

M3 - Article

C2 - 21472721

AN - SCOPUS:79953783840

VL - 117

SP - 1736

EP - 1744

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -